Lantheus Holdings Acquires Cerveau Technologies

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

Lantheus Acquires Life Molecular Imaging from Life Healthcare

July 22, 2025

Healthcare Services

Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.

Solve Therapeutics Acquires Cereius, a Duke University Spin-Out

June 22, 2023

Biotechnology

Solve Therapeutics, an oncology-focused biopharmaceutical company, has acquired Cereius, a Duke University spin-out that developed a site-specific radiolabeling chemistry platform for targeted radiodiagnostics and radiotherapeutics. The deal transfers Cereius’ platform and team into SolveTx to support development of targeted radionuclide therapeutics and companion diagnostics for oncology; Cereius shareholders will receive an undisclosed upfront payment plus potential milestone and royalty payments.

SHINE Technologies Acquires Lantheus' SPECT Business

January 2, 2026

Pharmaceuticals

SHINE Technologies has completed the acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and a portfolio of diagnostic radiopharmaceuticals (TechneLite, Cardiolite, NEUROLITE, Xenon Xe-133). SHINE named Michael Rossi CEO of SHINE SPECT USA, LLC and said the acquisition expands its nuclear medicine manufacturing capabilities and integrates with its Chrysalis Mo-99 production to strengthen isotope supply chain security.

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Biotechnology

AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.

Castle Biosciences Acquires Cernostics

October 19, 2021

Healthcare Services

Castle Biosciences (Nasdaq: CSTL) has completed the acquisition of Cernostics, Inc., a Pittsburgh-based developer of the TissueCypher spatial biology and AI-driven image analysis platform, for approximately $30 million in initial consideration plus up to $50 million in performance-based milestones. The deal brings the TissueCypher Barrett's Esophagus Assay into Castle's portfolio, expanding the company's diagnostics capabilities into the gastrointestinal and oncology markets and adding an estimated ~$1 billion to Castle's U.S. TAM.